Screener / SEC EDGAR /CIK 0000896622 /10-K filed Feb 6, 2026, compared with Feb 7, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Plastics Products

Aptargroup, Inc. ATR

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What ATR's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Oct 29, 2026, ATR reported $0.51 per share under GAAP and $1.52 on its own adjusted basis: the adjusted number is +198% above GAAP.

GAAP EPS $4.25, release Feb 8, 2024: Reported earnings per share increased 18% to $4.25 and adjusted earnings per share increased 24% to $4.78 Adjusted EPS $4.78, release Feb 8, 2024: Reported earnings per share increased 18% to $4.25 and adjusted earnings per share increased 24% to $4.78 +12% 2024-02 GAAP EPS $1.23, release Apr 25, 2024: Reported earnings per share increased 50% to $1.23 and adjusted earnings per share increased 31% to $1.26. Adjusted EPS $1.26, release Apr 25, 2024: Reported earnings per share increased 50% to $1.23 and adjusted earnings per share increased 31% to $1.26. +2% 2024-04 GAAP EPS $1.34, release Jul 25, 2024: Reported earnings per share increased 8% to $1.34 and adjusted earnings per share increased 12% to $1.37 Adjusted EPS $1.37, release Jul 25, 2024: Reported earnings per share increased 8% to $1.34 and adjusted earnings per share increased 12% to $1.37 +2% 2024-07 GAAP EPS $1.48, release Oct 24, 2024: Reported earnings per share increased 17% to $1.48 and adjusted earnings per share increased 6% to $1.49 Adjusted EPS $1.49, release Oct 24, 2024: Reported earnings per share increased 17% to $1.48 and adjusted earnings per share increased 6% to $1.49 +1% 2024-10 GAAP EPS $1.49, release Feb 6, 2025: Reported earnings per share increased 60% to $1.49 and adjusted earnings per share increased 27% to $1.52 Adjusted EPS $1.52, release Feb 6, 2025: Reported earnings per share increased 60% to $1.49 and adjusted earnings per share increased 27% to $1.52 +2% 2025-02 GAAP EPS $1.17, release May 1, 2025: Reported earnings per share of $1.17 Adjusted EPS $1.20, release May 1, 2025: Adjusted earnings per share of $1.20, excluding the impact of currency effects and change in tax rate, earnings per share would have increased 5% +3% 2025-05 GAAP EPS $1.67, release Jul 31, 2025: Reported earnings per share increased 25% to $1.67 and adjusted earnings per share increased 18% to $1.66 Adjusted EPS $1.66, release Jul 31, 2025: Reported earnings per share increased 25% to $1.67 and adjusted earnings per share increased 18% to $1.66 -1% 2025-07 GAAP EPS $4.75, release Oct 30, 2025: Reported net income increased 16% to $318 million and reported earnings per share increased 17% to $4.75 Adjusted EPS $4.48, release Oct 30, 2025: Adjusted earnings per share increased 7% to $4.48 -6% 2025-10 GAAP EPS $1.13, release Feb 5, 2026: Reported net income decreased 26% to $74 million and reported earnings per share decreased 24% to $1.13 Adjusted EPS $1.25, release Feb 5, 2026: Adjusted earnings per share were $1.25 +11% 2026-02 GAAP EPS $1.12, release Apr 30, 2026: Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12 Adjusted EPS $1.19, release Apr 30, 2026: Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency +6% 2026-04 GAAP EPS $1.36, release Jul 30, 2026: Reported second quarter earnings per share of $1.36 compared to $1.67 reported a year ago. Adjusted EPS $1.42, release Jul 30, 2026: Adjusted earnings per share were $1.42, compared to the prior year period’s adjusted earnings per share of $1.68, including comparable exchange rates. +4% 2026-07 GAAP EPS $0.51, release Oct 29, 2026: Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted EPS $1.52, release Oct 29, 2026: Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. +198% 2026-10
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. release
Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. release

What the company says its adjusted numbers leave out:

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. release Oct 29, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Aptar Reports Third Quarter 2026 Results

Open on SEC

Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year.

Reported net income was $33 million and reported earnings per share were $0.51, impacted by deconsolidation of the Russian subsidiary

Adjusted earnings per share were $1.52, at the higher end of the guidance range, compared to $1.62 in the prior year period at comparable exchange rates

Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends

Subsequent to the quarter, the Board of Directors approved an increase in the quarterly cash dividend from $0.48 to $0.50 “We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range. Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth. New technologies and development programs are expanding the role we can play with customers across the drug development cycle. Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully. These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.

For the quarter ended September 30, 2026, reported sales increased 6% to $1.02 billion compared to $961 million in the prior year and core sales increased 5% compared to the prior year period.

Third Quarter Segment Sales Analysis(Change Over Prior Year) Pharma Beauty Closures Total AptarGroup Reported Sales Growth 2% 9% 11% 6% Currency Effects(1) 1% 0% (1)% 0% Acquisitions / (2)% (1)% 1% (1)% Deconsolidation Core Sales Growth 1% 8% 11% 5%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. 1 Pharma’s reported sales increased 2% compared to the prior year period and c ore sales increased 1%. Adjusting for emergency medicine destocking, Pharma delivered 8% core sales growth in the quarter. Performance was supported by continued growth across a number of end markets, including central nervous system and pulmonary therapies, nasal decongestants, eye care and dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin of 36.4% a decline of 80 basis points, remaining above our long-term target despite a short-term unfavorable product mix related to destocking. Royalties and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 9% when compared to the prior year period, with core sales growth of 8%. There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications, and pass throughs of higher input costs also contributed positively. Adjusted EBITDA margin was 11.4%, a decline of 70 basis points, including unfavorable mix and ongoing challenges in North American operations.

Closures’ reported sales rose 11% from the prior year period, with c ore sales growth of 11%. Beverage and food sales grew significantly, led by strong demand for bottled water and concentrates, continued momentum from our latest beverage dispensing closure innovation, as well as strong condiment sales. Pass throughs of higher input costs contributed positively to core sales growth, however, the dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin to 15.5%.

During the third quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control. Aptar recorded a $58.0 million loss on deconsolidation which included approximately $30.0 million of cash held by the subsidiary. The combined impact was $61.2 million before tax, including approximately $2.6 million of related receivable reserves and $0.5 million of related legal costs; and $60.4 million after tax, or $0.94 per diluted share.

Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. The third quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the deconsolidation of the Russian subsidiary. The adjusted effective tax rate was 23.4%, compared to the prior year period’s reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.

For the nine months ended September 30, 2026, reported sales increased 8% to $3.03 billion compared to $2.81 billion in the prior year and core sales increased 2%.

Nine Months Year-To-Date Segment Sales Analysis(Change Over Prior Year) Pharma Beauty Closures Total AptarGroup Total Reported Sales 4% 12% 7% 8% Growth Currency Effects(1) (3)% (4)% (3)% (4)% Acquisitions / (1)% (4)% 1% (2)% Deconsolidation Core Sales Growth 0% 4% 5% 2%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. For the nine months ended September 30, 2026, Aptar’s reported earnings per share were $3.00, a decrease of 37%, which was also impacted by the deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ag o. For the first nine months of 2026, adj usted earnings per share were $4.13 and decreased 10% from prior year adjusted earnings per share of $4.60, including comparable exchange rates. The current year had a reported effective tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 20.4% and 21.9%, respectively. 2

Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking. Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth. Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies. In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally.”

Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5%. The earnings per share guidance range is assuming a 1.12 Euro to USD exchange rate.

During the third quarter, Aptar repurchased approximately 234 thousand shares for $30 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.50 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.

There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com. 3

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Core sales also exclude material acquisitions and, for the three and nine months ended September 30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs described above, which we exclude because they resulted from a government action rather than from the operations of our businesses and therefore do not reflect the underlying performance of our remaining operations. For the three and nine months ended September 30, 2026 and 2025, “Other special items” include costs incurred related to non-ordinary-cour se litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non- GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition- related costs and other special items. 4 This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries and certain supply chain disruptions; as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate and cash flow; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key products or accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, interest rate volatility; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather- related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Nine Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash Flows from Operating Activities: Net income $ 193,599 $ 318,227 Adjustments to reconcile net income to net cash provided by operations: Depreciation 198,044 177,412 Amortization 32,866 33,373 Stock-based compensation 33,043 36,772 Provision for CECL 4,374 516 Loss (gain) on disposition of fixed 484 77 assets Loss on Russia deconsolidation 58,020 — Net loss (gain) on remeasurement of 1,160 -845 equity securities Deferred income taxes -5,257 -31,851 Defined benefit plan expense 6,898 10,232 Equity in results of affiliates -3,224 -6,142 Gain on remeasurement of equity method — -26,518 investment Impairment loss 5,007 — Changes in balance sheet items, excluding effects from foreign currency adjustments:

Accounts and other receivables -101,728 -66,812 Inventories -56,698 -22,782 Prepaid and other current assets -17,906 -28,064 Accounts payable, accrued and other 60,132 6,950 liabilities Income taxes payable -5,250 -1,281 Retirement and deferred compensation -6,183 -5,891 plan liabilities Retirement and deferred compensation 420 -7,314 plan assets Other changes, net -8,023 247 Net Cash Provided by Operations 389,778 386,306 Cash Flows from Investing Activities: Capital expenditures -191,965 -183,600 Proceeds from government grants — 3,308 Proceeds from sale of property, plant 1,544 2,103 and equipment (Purchases) and maturities of short-term -1,462 2,813 investments Acquisition of business, net of cash -156 -28,221 acquired and release of escrow Acquisition of intangible assets, net -1,933 -4,301 Investment in equity securities — -7,258 Cash balance of deconsolidated -29,977 — subsidiary Notes receivable, net 1,355 37 Net Cash Used by Investing Activities -222,594 -215,119 Cash Flows from Financing Activities: Proceeds from notes payable and 20,826 2,105 overdrafts Repayments of notes payable and -21,281 -1,946 overdrafts Proceeds of short term revolving credit 50,000 144,620 facility, net Proceeds from long-term obligations 6,112 1,204 Repayments of long-term obligations -160,897 -36,490 Payment of contingent consideration -3,730 — obligation Dividends paid -92,054 -89,287 Proceeds from stock option exercises 22,420 14,869 Purchase of treasury stock -179,973 -190,005 Redeemable noncontrolling interest 1,106 703 Net Cash Used by Financing Activities -357,471 -154,227 Effect of Exchange Rate Changes on Cash -7,961 16,253 Net Decrease in Cash and Equivalents and -198,248 33,213 Restricted Cash Cash and Equivalents and Restricted Cash 404,849 223,844 at Beginning of Period Cash and Equivalents and Restricted Cash $ 206,601 $ 257,057 at End of Period

Three Nine Months Months Ended Ended September September 2026 30, 2025 2026 30, 2025 ────────────────────────────────────────────────────────────────────────────── Net Income Attribu… to $ 0.51 $ 1.92 $ 3.00 $ 4.75 AptarGr… Inc. Per Diluted Share Adjustm… Restruc… 0.02 0.02 0.05 0.06 initiat… Net investm… 0.01 — 0.01 -0.01 loss (gain) Realized gain on investm… included in — — — — net investm… loss (gain) above Russia 0.94 — 0.94 — deconso… Gain from remeasu… of — -0.40 — -0.40 equity method investm… Transac… costs related — 0.01 — 0.01 to acquisi… Purchase account… adjustm… related — 0.02 — 0.02 to acquisi… and investm… Other special 0.04 0.05 0.13 0.05 items Foreign currency — 0.12 effects (1) Adjusted Net Income Attribu… to $ 1.52 $ 1.62 $ 4.13 $ 4.60 AptarGr… Inc. Per Diluted Share

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. 13

Three Months Ending December 31, Expected 2026 2025 ────────────────────────────────────────────────────────────────────────────── Income before Income Taxes $ 91,522 Adjustments: Restructuring initiatives 4,048 Curtailment gain related to -115 restructuring initiatives Net investment loss 1,328 Transaction costs related to 368 acquisitions Purchase accounting adjustments related 645 to acquisitions and investments Other special items 3,960 Foreign currency effects (1) -2,485 Adjusted Earnings before Income Taxes $ 99,271 Provision for Income Taxes $ 17,252 Adjustments: Restructuring initiatives 1,015 Curtailment gain related to -30 restructuring initiatives Net investment loss 325 Transaction costs related to 125 acquisitions Purchase accounting adjustments related 110 to acquisitions and investments Other special items 970 Foreign currency effects (1) -468 Adjusted Provision for Income Taxes $ 19,299 Net Loss Attributable to Noncontrolling $ 130 Interests Net Income Attributable to Redeemable $ -56 Noncontrolling Interests Net Income Attributable to AptarGroup, $ 74,344 Inc. Adjustments: Restructuring initiatives 3,033 Curtailment gain related to -85 restructuring initiatives Net investment loss 1,003 Transaction costs related to 243 acquisitions Purchase accounting adjustments related 535 to acquisitions and investments Other special items 2,990 Foreign currency effects (1) -2,017 Adjusted Net Income Attributable to $ 80,046 AptarGroup, Inc. Average Number of Diluted Shares 65,796 Outstanding

Three Months Ending December 31, Expected 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net Income Attributable to AptarGroup, $ 1.13 Inc. Per Diluted Share Adjustments: Restructuring initiatives 0.05 Curtailment gain related to — restructuring initiatives Net investment loss 0.01 Transaction costs related to — acquisitions Purchase accounting adjustments related 0.01 to acquisitions and investments Other special items 0.05 Foreign currency effects (1) -0.03 Adjusted Net Income Attributable to $1.39 - $1.47 $ 1.22 AptarGroup, Inc. Per Diluted Share (2)

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the fourth quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per share and 19.4% on adjusted earnings per share. 16

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                    Aptar Reports Third Quarter 2026 Results                    
                                                                                
Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a
global leader in drug delivery, dosing and protection technologies, and consumer
product dispensing, today reported the following third quarter results for the
period ended September 30, 2026, as compared to the corresponding period of the
last fiscal year.
                                                                                
  Third Quarter 2026 Highlights                                                 
                                                                                
(Compared to the prior year quarter; see Non-GAAP section for full definitions;
see reconciliation for Non-GAAP measures)
                                                                                
  •                                                                             
                                                                                
Reported sales increased 6% and core sales increased 5%
                                                                                
  •                                                                             
                                                                                
Reported net income was $33 million and reported earnings per share were $0.51,
impacted by deconsolidation of the Russian subsidiary
                                                                                
  •                                                                             
                                                                                
Adjusted earnings per share were $1.52, at the higher end of the guidance range,
compared to $1.62 in the prior year period at comparable exchange rates
                                                                                
  •                                                                             
                                                                                
Adjusted EBITDA margin was 21.3%, compared to 23.2% in the prior year quarter
                                                                                
  •                                                                             
                                                                                
Returned $61 million in the quarter and $272 million year-to-date to
shareholders through share repurchases and dividends
                                                                                
  •                                                                             
                                                                                
Subsequent to the quarter, the Board of Directors approved an increase in the
quarterly cash dividend from $0.48 to $0.50
“We delivered broad-based revenue growth across all three segments. Pharma
delivered impressive growth in central nervous system therapies, pulmonary,
injectables and consumer healthcare, while maintaining profitability at the high
end of our long-term target range. Our Pharma pipeline remains strong, with
continued focus on building the pipeline and converting opportunities into
future growth. New technologies and development programs are expanding the role
we can play with customers across the drug development cycle. Beauty and
Closures also delivered strong top-line growth, including double-digit core
sales growth in Closures, where innovation in beverage dispensing continues to
gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our
position with customers, accelerate innovation, execute with greater consistency
and allocate capital thoughtfully. These priorities will guide how we drive
profitable growth and create long-term value for Aptar and our shareholders,”
said Gael Touya, Aptar President and CEO.
                                                                                
   Third Quarter Results                                                        
                                                                                
For the quarter ended September 30, 2026, reported sales increased 6% to $1.02
billion compared to $961 million in the prior year and core sales increased 5%
compared to the prior year period.
                                                                                
  Third Quarter Segment                                                         
  Sales                                                                         
  Analysis(Change Over                                                          
  Prior Year)                                                                   
                              Pharma    Beauty    Closures    Total AptarGroup  
  Reported Sales Growth       2%        9%        11%         6%                
  Currency Effects(1)         1%        0%        (1)%        0%                
  Acquisitions /              (2)%      (1)%      1%          (1)%              
  Deconsolidation                                                               
  Core Sales Growth           1%        8%        11%         5%                
                                                                                
(1) - Currency effects are approximated by translating last year's amounts at
this year's foreign exchange rates.
                                       1                                        
Pharma’s reported sales increased 2% compared to the prior year period and c ore
sales increased 1%. Adjusting for emergency medicine destocking, Pharma
delivered 8% core sales growth in the quarter. Performance was supported by
continued growth across a number of end markets, including central nervous
system and pulmonary therapies, nasal decongestants, eye care and dermal drug
delivery solutions, and demand related to biologics, vaccines and GLP-1
therapies. These growth drivers were partially offset by the anticipated
reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin
of 36.4% a decline of 80 basis points, remaining above our long-term target
despite a short-term unfavorable product mix related to destocking. Royalties
and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 9% when compared to the prior year period,
with core sales growth of 8%. There was increased demand for prestige fragrance
dispensing, color cosmetics, as well as hair care applications, and pass
throughs of higher input costs also contributed positively. Adjusted EBITDA
margin was 11.4%, a decline of 70 basis points, including unfavorable mix and
ongoing challenges in North American operations.

Closures’ reported sales rose 11% from the prior year period, with c ore sales
growth of 11%. Beverage and food sales grew significantly, led by strong demand
for bottled water and concentrates, continued momentum from our latest beverage
dispensing closure innovation, as well as strong condiment sales. Pass throughs
of higher input costs contributed positively to core sales growth, however, the
dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin
to 15.5%.

During the third quarter, Aptar deconsolidated its Russian subsidiary following
a governmental decree placing the subsidiary under external administration and
the resulting loss of control. Aptar recorded a $58.0 million loss on
deconsolidation which included approximately $30.0 million of cash held by the
subsidiary. The combined impact was $61.2 million before tax, including
approximately $2.6 million of related receivable reserves and $0.5 million of
related legal costs; and $60.4 million after tax, or $0.94 per diluted share.

Reported third quarter earnings per share were $0.51 compared to $1.92 reported
a year ago. Adjusted earnings per share were $1.52, compared to the prior year
period’s adjusted earnings per share of $1.62, including comparable exchange
rates. The third quarter reported effective tax rate was 45.6%, reflecting the
non-deductible tax impact of the deconsolidation of the Russian subsidiary. The
adjusted effective tax rate was 23.4%, compared to the prior year period’s
reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.
                                                                                
   Nine Months Year-to-Date Results                                             
                                                                                
For the nine months ended September 30, 2026, reported sales increased 8% to
$3.03 billion compared to $2.81 billion in the prior year and core sales
increased 2%.
                                                                                
  Nine Months Year-To-Date                                                      
  Segment Sales                                                                 
  Analysis(Change Over                                                          
  Prior Year)                                                                   
                              Pharma    Beauty    Closures    Total AptarGroup  
  Total Reported Sales        4%        12%       7%          8%                
  Growth                                                                        
  Currency Effects(1)         (3)%      (4)%      (3)%        (4)%              
  Acquisitions /              (1)%      (4)%      1%          (2)%              
  Deconsolidation                                                               
  Core Sales Growth           0%        4%        5%          2%                
                                                                                
(1) - Currency effects are approximated by translating last year's amounts at
this year's foreign exchange rates.
For the nine months ended September 30, 2026, Aptar’s reported earnings per
share were $3.00, a decrease of 37%, which was also impacted by the
deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ag
o. For the first nine months of 2026, adj usted earnings per share were $4.13
and decreased 10% from prior year adjusted earnings per share of $4.60,
including comparable exchange rates. The current year had a reported effective
tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the
prior year reported and adjusted effective tax rates of 20.4% and 21.9%,
respectively.
                                       2                                        
                                                                                
  Outlook                                                                       
                                                                                
Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year
strong, supported by continued Pharma growth, particularly in consumer
healthcare and injectables and without the headwind from emergency medicine
destocking. Our Pharma pipeline remains strong, with new technologies and
development programs expanding our reach across therapeutic areas and advancing
opportunities for future growth. Closures continues its great momentum, with
innovation helping drive increased demand, particularly for our beverage
technologies. In Beauty, we remain focused on improving our long-term North
American trajectory, while we continue to see pockets of healthy demand in
areas, such as prestige fragrance, globally.”

Aptar currently expects adjusted earnings per share for the fourth quarter of
2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective
tax rate range of 17.5% to 19.5%. The earnings per share guidance range is
assuming a 1.12 Euro to USD exchange rate.
                                                                                
  Cash Dividends and Share Repurchases                                          
                                                                                
During the third quarter, Aptar repurchased approximately 234 thousand shares
for $30 million. Aptar may repurchase shares through the open market, privately
negotiated transactions or other programs, subject to market conditions. As
previously announced, Aptar’s Board of Directors approved a quarterly cash
dividend of $0.50 per share. The payment date is December 3, 2026, to
stockholders of record as of November 12, 2026.
                                                                                
  Open Conference Call                                                          
                                                                                
There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m.
Central Time to discuss the company’s third quarter results for 2026. The call
will last approximately one hour. Interested parties are invited to listen to a
live webcast by visiting the Investor Relations website at investors.aptar.com.
Replay of the conference call can also be accessed for a limited time on the
Investor Relations page of the website.
                                                                                
  About Aptar                                                                   
                                                                                
Aptar is a global leader in drug delivery, dosing and protection technologies,
and consumer product dispensing. Aptar partners with the world’s top healthcare
and consumer brands to deliver medicines and create exceptional user
experiences. Serving diverse markets, from pharmaceutical to beauty to food and
beverage, Aptar combines market expertise with proprietary design, engineering
and science to develop innovative solutions that help improve lives worldwide.
Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people
across 20 countries. Learn more at http://www.aptar.com.
                                       3                                        
                                                                                
  Presentation of Non-GAAP Information                                          
                                                                                
This press release refers to certain non-GAAP financial measures, including
current year adjusted earnings per share and adjusted EBITDA, which exclude the
impact of restructuring initiatives, acquisition-related costs, certain purchase
accounting adjustments related to acquisitions and investments, gains from
remeasurement of equity method investments and net unrealized investment gains
and losses related to observable market price changes on equity securities,
Russia deconsolidation impacts, and other special items. Core sales and adjusted
earnings per share also neutralize the impact of foreign currency translation
effects when comparing current results to the prior year. Core sales also
exclude material acquisitions and, for the three and nine months ended September
30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA
is defined as earnings before net interest, taxes, depreciation, amortization,
restructuring initiatives, acquisition-related costs, purchase accounting
adjustments related to acquisitions and investments, gains from remeasurement of
equity method investments, net unrealized investment gains and losses related to
observable market price changes on equity securities, Russia deconsolidation
impacts, and other special items. Russia deconsolidation impacts comprise the
loss on deconsolidation of our Russian subsidiary and related receivable
reserves and legal costs described above, which we exclude because they resulted
from a government action rather than from the operations of our businesses and
therefore do not reflect the underlying performance of our remaining operations.
For the three and nine months ended September 30, 2026 and 2025, “Other special
items” include costs incurred related to non-ordinary-cour se litigation,
specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving
Aptar’s claims of trade-secret misappropriation and contractual breaches and
ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement
actions filed by Nemera La Verpillière SAS in Germany and France relating to
certain of Aptar’s ophthalmic products. These costs are excluded because they do
not reflect our core operating performance. Please refer to “Legal Proceedings”
within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the
year ended December 31, 2025 and subsequent SEC filings for more information.
Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-
GAAP financial measures may not be comparable to similarly titled non-GAAP
financial measures provided by other companies. Aptar’s management believes
these non-GAAP financial measures provide useful information to our investors
because they allow for a better period over period comparison of operating
results by removing the impact of items that, in management’s view, do not
reflect Aptar’s core operating performance. These non-GAAP financial measures
also provide investors with certain information used by Aptar’s management when
making financial and operational decisions. Free cash flow is calculated as cash
provided by operating activities less capital expenditures plus proceeds from
government grants related to capital expenditures. We use free cash flow to
measure cash flow generated by operations that is available for dividends, share
repurchases, acquisitions and debt repayment. We believe that it is meaningful
to investors in evaluating our financial performance and measuring our ability
to generate cash internally to fund our initiatives. These non-GAAP financial
measures should not be considered in isolation or as a substitute for GAAP
financial results but should be read in conjunction with the unaudited condensed
consolidated statements of income and other information presented herein. A
reconciliation of non-GAAP financial measures to the most directly comparable
GAAP measures is included in the accompanying tables. Our outlook is provided on
a non-GAAP basis because certain reconciling items are dependent on future
events that either cannot be controlled, such as exchange rates and changes in
the fair value of equity investments, or reliably predicted because they are not
part of our routine activities, such as restructuring initiatives, acquisition-
related costs and other special items.
                                       4                                        
This press release contains forward-looking statements, including certain
statements set forth under the “Outlook” section of this press release. Words
such as “expects,” “anticipates,” “believes,” “estimates,” “future,”
“potential,” “continues” and other similar expressions or future or conditional
verbs such as “will,” “should,” “would” and “could” are intended to identify
such forward-looking statements. Forward-looking statements are made pursuant to
the safe harbor provisions of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs
as well as assumptions made by and information currently available to us.
Accordingly, our actual results or other events may differ materially from those
expressed or implied in such forward-looking statements due to known or unknown
risks and uncertainties that exist in our operations and business environment
including, but not limited to: geopolitical conflicts worldwide and the
resulting indirect impact on demand from our customers selling their products
into these countries and certain supply chain disruptions; as well as
governmental actions affecting our foreign operations and assets, including the
loss of control over, and our ability to recover value from, our Russian
operations; cybersecurity threats against our systems and/or service providers
that could impact our networks and reporting systems; the availability of raw
materials and components (particularly from sole sourced suppliers for some of
our Pharma solutions) as well as the financial viability of these suppliers; our
ability to protect and defend our intellectual property rights, as well as
litigation involving intellectual property rights; the outcome of any legal
proceeding that has been or may be instituted against us and others; our ability
to keep pace with competition and technological advances, including in
connection with the shifting of Pharma origination to less regulated markets;
lower demand and asset utilization due to an economic recession either globally
or in key markets we operate within; economic conditions worldwide, including
inflationary conditions and potential deflationary conditions in other regions
we rely on for growth; significant tariffs and other restrictions on foreign
imports imposed by the U.S. and related countermeasures taken by impacted
foreign countries; our ability to successfully implement facility expansions and
new facility projects; fluctuations in the cost of materials, components,
transportation cost as a result of supply chain disruptions and labor shortages,
and other input costs; significant fluctuations in foreign currency exchange
rates or our effective tax rate and cash flow; the impact of tax reform
legislation, changes in tax rates and other tax-related events or transactions
that could impact our effective tax rate; financial conditions of customers and
suppliers; consolidations within our customer or supplier bases; changes in
customer and/or consumer spending levels; loss of one or more key products or
accounts; our ability to offset inflationary impacts with cost containment,
productivity initiatives and price increases; changes in capital availability or
cost, interest rate volatility; loss of royalty revenue due to contract
expirations; volatility of global credit markets; our ability to identify
potential new acquisitions and to successfully acquire and integrate such
operations, including the successful integration of the businesses we have
acquired; our ability to build out acquired businesses and integrate the
product/service offerings of the acquired entities into our existing
product/service portfolio; direct or indirect consequences of acts of war,
terrorism or social unrest; the impact of natural disasters and other weather-
related occurrences; fiscal and monetary policies and other regulations;
changes, difficulties or failures in complying with government regulation,
including FDA or similar foreign governmental authorities; changing regulations
or market conditions regarding environmental sustainability; our ability to
retain key members of management and manage labor costs; work stoppages due to
labor disputes; our ability to meet future cash flow estimates to support our
goodwill impairment testing; the demand for existing and new products; the
success of our customers’ products, particularly in the pharmaceutical industry;
our ability to manage worldwide customer launches of complex technical products,
particularly in developing markets; difficulties in product development and
uncertainties related to the timing or outcome of product development;
significant product liability claims; and other risks associated with our
operations. For additional information on these and other risks and
uncertainties, please see our filings with the Securities and Exchange
Commission, including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” in our
Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on
forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.
                                                                                
  Contacts                                                                      
                                                                                
                                                                                
  Investor Relations Contact                                                    
                                                                                
:

Mary Skafidas

[email protected]

815-479-5530

Media Contact:

Katie Reardon

[email protected]

815-479-5671
                                       5                                        
                                                                                
                                AptarGroup, Inc.                                
                                                                                
                                                                                
            Condensed Consolidated Financial Statements (Unaudited)             
                                                                                
                     (In Thousands, Except Per Share Data)                      
                                                                                
                       Consolidated Statements of Income                        
                                                                                
                                                                                
                     Three                              Nine                    
                    Months                            Months                    
                     Ended                             Ended                    
                  Septemb…                           Septem…                    
            2026       30,    2025             2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net       $     1,019,1…    $     961,131    $     3,028,…    $     2,814,4…  
  Sales                                                                         
  Cost                                                                          
  of                                                                            
  Sales                                                                         
  (excl…                                                                        
  of               646,196          598,046          1,938,…          1,747,9…  
  depre…                                                                        
  and                                                                           
  amort…                                                                        
  shown                                                                         
  below)                                                                        
  Selli…                                                                        
  Resea…                                                                        
  &                160,164          148,760          485,501           455,176  
  Devel…                                                                        
  and                                                                           
  Admin…                                                                        
  Depre…                                                                        
  and               75,544           75,234          230,910           210,785  
  Amort…                                                                        
  Restr…             2,208            2,168            4,713             5,789  
  Initi…                                                                        
  Opera…           135,007          136,923          369,225           394,764  
  Income                                                                        
  Other                                                                         
  Income                                                                        
  (Expe…                                                                        
  Inter…           -15,790          -13,532          -48,733           -35,733  
  Expen…                                                                        
  Inter…             1,930            2,400            8,359             7,094  
  Income                                                                        
  Net                                                                           
  Inves…            -1,011             -161           -1,160               845  
  (Loss)                                                                        
  Gain                                                                          
  Loss                                                                          
  on               -58,020                —          -58,020                 —  
  Russia                                                                        
  Decon…                                                                        
  Equity                                                                        
  in                                                                            
  Resul…             1,106            1,747            3,224             6,142  
  of                                                                            
  Affil…                                                                        
  Gain                                                                          
  from                                                                          
  Remea…                                                                        
  of                     —           26,518                —            26,518  
  Equity                                                                        
  Method                                                                        
  Inves…                                                                        
  Misce…                                                                        
  Expen…            -2,889              232           -3,744               226  
  net                                                                           
  Income                                                                        
  before            60,333          154,127          269,151           399,856  
  Income                                                                        
  Taxes                                                                         
  Provi…                                                                        
  for               27,511           26,295           75,552            81,629  
  Income                                                                        
  Taxes                                                                         
  Net       $       32,822    $     127,832    $     193,599    $      318,227  
  Income                                                                        
  Net                                                                           
  (Inco…                                                                        
  Loss                                                                          
  Attri…              -226              -47             -382                76  
  to                                                                            
  Nonco…                                                                        
  Inter…                                                                        
  Net                                                                           
  Loss                                                                          
  (Inco…                                                                        
  Attri…                 6              142             -368               142  
  to                                                                            
  Redee…                                                                        
  Nonco…                                                                        
  Inter…                                                                        
  Net                                                                           
  Income                                                                        
  Attri…    $       32,602    $     127,927    $     192,849    $      318,445  
  to                                                                            
  Aptar…                                                                        
  Inc.                                                                          
  Net                                                                           
  Income                                                                        
  Attri…                                                                        
  to                                                                            
  Aptar…                                                                        
  Inc.                                                                          
  per                                                                           
  Common                                                                        
  Share:                                                                        
                                                                                
  Basic     $         0.51    $        1.95    $        3.03    $         4.83  
  Dilut…    $         0.51    $        1.92    $        3.00    $         4.75  
  Avera…                                                                        
  Numbe…                                                                        
  of                                                                            
  Shares                                                                        
  Outst…                                                                        
  Basic             63,523           65,709           63,733            65,989  
  Dilut…            64,147           66,630           64,373            67,043  
                                                                                
                                       6                                        
                                                                                
                                AptarGroup, Inc.                                
                                                                                
                                                                                
            Condensed Consolidated Financial Statements (Unaudited)             
                                                                                
                                  (continued)                                   
                                                                                
                                ($ In Thousands)                                
                                                                                
                          Consolidated Balance Sheets                           
                                                                                
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Cash and Equivalents           $             204,176    $            402,424  
  Short-term Investments                         8,121                   7,109  
  Accounts and Notes                           883,939                 803,830  
  Receivable, Net                                                               
  Inventories                                  582,605                 537,845  
  Prepaid and Other                            157,950                 142,354  
  Total Current Assets                       1,836,791               1,893,562  
  Property, Plant and                        1,635,530               1,676,479  
  Equipment, Net                                                                
  Goodwill                                   1,067,152               1,077,898  
  Other Assets                                 572,153                 604,780  
  Total Assets                   $           5,111,626    $          5,252,719  
  LIABILITIES, MEZZANINE                                                        
  EQUITY AND                                                                    
  STOCKHOLDERS’ EQUITY                                                          
  Short-Term Obligations         $             350,681    $            343,531  
  Accounts Payable, Accrued                                                     
  and Other                                    872,133                 822,913  
  Liabilities                                                                   
  Total Current Liabilities                  1,222,814               1,166,444  
  Long-Term Obligations                      1,024,735               1,139,433  
  Deferred Liabilities and                     202,894                 234,617  
  Other                                                                         
  Total Liabilities                          2,450,443               2,540,494  
  Redeemable Noncontrolling                     28,048                  26,244  
  Interests                                                                     
  Total Mezzanine Equity                        28,048                  26,244  
  AptarGroup, Inc.                           2,614,324               2,668,096  
  Stockholders' Equity                                                          
  Noncontrolling Interests in                   18,811                  17,885  
  Subsidiaries                                                                  
  Total Stockholders' Equity                 2,633,135               2,685,981  
  Total Liabilities,                                                            
  Mezzanine Equity and           $           5,111,626    $          5,252,719  
  Stockholders' Equity                                                          
                                                                                
                                       7                                        
                                                                                
                                AptarGroup, Inc.                                
                                                                                
                                                                                
            Condensed Consolidated Financial Statements (Unaudited)             
                                                                                
                                  (continued)                                   
                                                                                
                                ($ In Thousands)                                
                                                                                
                      Consolidated Statement of Cash Flows                      
                                                                                
                                                                                
  Nine Months Ended September 30,             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Cash Flows from Operating Activities:                                         
  Net income                                  $      193,599    $      318,227  
  Adjustments to reconcile net income to                                        
  net cash provided by operations:                                              
  Depreciation                                       198,044           177,412  
  Amortization                                        32,866            33,373  
  Stock-based compensation                            33,043            36,772  
  Provision for CECL                                   4,374               516  
  Loss (gain) on disposition of fixed                    484                77  
  assets                                                                        
  Loss on Russia deconsolidation                      58,020                 —  
  Net loss (gain) on remeasurement of                  1,160              -845  
  equity securities                                                             
  Deferred income taxes                               -5,257           -31,851  
  Defined benefit plan expense                         6,898            10,232  
  Equity in results of affiliates                     -3,224            -6,142  
  Gain on remeasurement of equity method                   —           -26,518  
  investment                                                                    
  Impairment loss                                      5,007                 —  
  Changes in balance sheet items,                                               
  excluding effects from foreign currency                                       
  adjustments:                                                                  
                                                                                
  Accounts and other receivables                    -101,728           -66,812  
  Inventories                                        -56,698           -22,782  
  Prepaid and other current assets                   -17,906           -28,064  
  Accounts payable, accrued and other                 60,132             6,950  
  liabilities                                                                   
  Income taxes payable                                -5,250            -1,281  
  Retirement and deferred compensation                -6,183            -5,891  
  plan liabilities                                                              
  Retirement and deferred compensation                   420            -7,314  
  plan assets                                                                   
  Other changes, net                                  -8,023               247  
  Net Cash Provided by Operations                    389,778           386,306  
  Cash Flows from Investing Activities:                                         
  Capital expenditures                              -191,965          -183,600  
  Proceeds from government grants                          —             3,308  
  Proceeds from sale of property, plant                1,544             2,103  
  and equipment                                                                 
  (Purchases) and maturities of short-term            -1,462             2,813  
  investments                                                                   
  Acquisition of business, net of cash                  -156           -28,221  
  acquired and release of escrow                                                
  Acquisition of intangible assets, net               -1,933            -4,301  
  Investment in equity securities                          —            -7,258  
  Cash balance of deconsolidated                     -29,977                 —  
  subsidiary                                                                    
  Notes receivable, net                                1,355                37  
  Net Cash Used by Investing Activities             -222,594          -215,119  
  Cash Flows from Financing Activities:                                         
  Proceeds from notes payable and                     20,826             2,105  
  overdrafts                                                                    
  Repayments of notes payable and                    -21,281            -1,946  
  overdrafts                                                                    
  Proceeds of short term revolving credit             50,000           144,620  
  facility, net                                                                 
  Proceeds from long-term obligations                  6,112             1,204  
  Repayments of long-term obligations               -160,897           -36,490  
  Payment of contingent consideration                 -3,730                 —  
  obligation                                                                    
  Dividends paid                                     -92,054           -89,287  
  Proceeds from stock option exercises                22,420            14,869  
  Purchase of treasury stock                        -179,973          -190,005  
  Redeemable noncontrolling interest                   1,106               703  
  Net Cash Used by Financing Activities             -357,471          -154,227  
  Effect of Exchange Rate Changes on Cash             -7,961            16,253  
  Net Decrease in Cash and Equivalents and          -198,248            33,213  
  Restricted Cash                                                               
  Cash and Equivalents and Restricted Cash           404,849           223,844  
  at Beginning of Period                                                        
  Cash and Equivalents and Restricted Cash    $      206,601    $      257,057  
  at End of Period                                                              
                                                                                
                                       8                                        
                                                                                
                                AptarGroup, Inc.                                
                                                                                
 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)  
                                                                                
                                ($ In Thousands)                                
                                                                                
       T…                                                                       
       M…                                                                       
       E…                                                                       
       S…                                                                       
       3…                                                                       
       2…                                                                       
 ────────────────────────────────────────────────────────────────────────────── 
                                                            C…         N…       
       C…           P…           B…           C…            &          I…       
                                                            O…                  
  …    $   1…       $   4…       $   3…       $   20…       $     —    $     —  
  …                                                                             
  …                                                                             
  …    $   3…                                                                   
  …                                                                             
  …                                                                             
  …        2…                                                                   
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…           1…           5…           -2…           -3…        -1…  
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           4…           1…           -25             —             
  …                                                                             
  …                                                                             
  …        1…            —            —             —           1,…             
  …                                                                             
  …                                                                             
  …        6…           3…           9…           40…           7,…             
  …                                                                             
  …                                                                             
  …        3…           3…            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…           1…           17…           -2…        -1…  
  …                                                                             
  …                                                                             
  …        1…                                                              15…  
  …                                                                             
  …        -…                                                              -1…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…           1…           17…           -2…          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…           3…           2…           14…           1,…             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   2…       $   1…       $   4…       $   32…       $   -2…    $     —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…  %                                                                
  …                                                                             
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…  %        3…  %        1…  %        15…  %                        
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
                                                                                
       T…                                                                       
       M…                                                                       
       E…                                                                       
       S…                                                                       
       3…                                                                       
       2…                                                                       
 ────────────────────────────────────────────────────────────────────────────── 
                                                            C…         N…       
       C…           P…           B…           C…            &          I…       
                                                            O…                  
  …    $   9…       $   4…       $   3…       $   18…       $     —    $     —  
  …                                                                             
  …                                                                             
  …    $   1…                                                                   
  …                                                                             
  …                                                                             
  …        2…                                                                   
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…           4…           14…           -1…        -1…  
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           9…           5…           702            -3             
  …                                                                             
  …                                                                             
  …        1…            —            —             —           161             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —           -…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…           5…           1…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…            —           1…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…           4…            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…           1…           15…           -1…        -1…  
  …                                                                             
  …                                                                             
  …        1…                                                              13…  
  …                                                                             
  …        -…                                                              -2…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…           1…           15…           -1…          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…           3…           2…           14…           874             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   2…       $   1…       $   3…       $   30…       $   -1…    $     —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…  %                                                                
  …                                                                             
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…  %        3…  %        1…  %        16…  %                        
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
                                       9                                        
                                                                                
                                AptarGroup, Inc.                                
                                                                                
 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)  
                                                                                
                                ($ In Thousands)                                
                                                                                
       N…                                                                       
       M…                                                                       
       E…                                                                       
       S…                                                                       
       3…                                                                       
       2…                                                                       
 ────────────────────────────────────────────────────────────────────────────── 
                                                            C…         N…       
       C…           P…           B…           C…            &          I…       
                                                            O…                  
  …    $   3…       $   1…       $   1…       $   58…       $     —    $     —  
  …                                                                             
  …                                                                             
  …    $   1…                                                                   
  …                                                                             
  …                                                                             
  …        7…                                                                   
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           3…           3…           1,…           -7…        -4…  
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…           3…           4…           311           -4…             
  …                                                                             
  …                                                                             
  …        1…            —            —             —           1,…             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        88            —            —             —            88             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…           3…           9…           40…           7,…             
  …                                                                             
  …                                                                             
  …                                                                             
  …        83           83            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           1…            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           3…           5…           42…           -6…        -4…  
  …                                                                             
  …                                                                             
  …        4…                                                              48…  
  …                                                                             
  …        -…                                                              -8…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           3…           5…           42…           -6…          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           1…           7…           43…           3,…             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   6…       $   4…       $   1…       $   85…       $   -5…    $     —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…  %                                                                
  …                                                                             
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…  %        3…  %        1…  %        14…  %                        
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
                                       10                                       
                                                                                
                                AptarGroup, Inc.                                
                                                                                
 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)  
                                                                                
                                ($ In Thousands)                                
                                                                                
       N…                                                                       
       M…                                                                       
       E…                                                                       
       S…                                                                       
       3…                                                                       
       2…                                                                       
 ────────────────────────────────────────────────────────────────────────────── 
                                                            C…         N…       
       C…           P…           B…           C…            &          I…       
                                                            O…                  
  …    $   2…       $   1…       $   9…       $   54…       $     —    $     —  
  …                                                                             
  …                                                                             
  …    $   3…                                                                   
  …                                                                             
  …                                                                             
  …        8…                                                                   
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           3…           8…           44…           -5…        -2…  
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           1…           1…           2,…            97             
  …                                                                             
  …                                                                             
  …        -…            —            —             —           -8…             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —           -…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           5…           5…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…            —           1…             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…           4…            —             —             —             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           3…           5…           47…           -5…        -2…  
  …                                                                             
  …                                                                             
  …        3…                                                              35…  
  …                                                                             
  …        -…                                                              -7…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…           3…           5…           47…           -5…          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           1…           6…           41…           2,…          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   6…       $   4…       $   1…       $   89…       $   -5…    $     —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…  %                                                                
  …                                                                             
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…  %        3…  %        1…  %        16…  %                        
  /                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
                                       11                                       
                                                                                
                                AptarGroup, Inc.                                
                                                                                
       Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)        
                                                                                
                     (In Thousands, Except Per Share Data)                      
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Income                                                                        
  before     $      60,333    $     154,127    $      269,151    $     399,856  
  Income                                                                        
  Taxes                                                                         
  Adjust…                                                                       
  Restru…            2,208            2,168             4,713            5,789  
  initia…                                                                       
  Net                                                                           
  invest…            1,011              161             1,160             -845  
  loss                                                                          
  (gain)                                                                        
  Realiz…                                                                       
  gain on                                                                       
  invest…                                                                       
  includ…                                                                       
  in                     —                —                88                —  
  net                                                                           
  invest…                                                                       
  loss                                                                          
  (gain)                                                                        
  above                                                                         
  Russia                                                                        
  decons…           61,161                —            61,161                —  
  impact                                                                        
  Gain                                                                          
  from                                                                          
  remeas…                                                                       
  of                     —          -26,518                 —          -26,518  
  equity                                                                        
  method                                                                        
  invest…                                                                       
  Transa…                                                                       
  costs                                                                         
  related                —              748                83            1,092  
  to                                                                            
  acquis…                                                                       
  Purcha…                                                                       
  accoun…                                                                       
  adjust…                                                                       
  related                —            1,148               145            1,148  
  to                                                                            
  acquis…                                                                       
  and                                                                           
  invest…                                                                       
  Other                                                                         
  special            3,095            4,400            10,899            4,400  
  items                                                                         
  Foreign                                                                       
  curren…                              -371                              9,866  
  effects                                                                       
  (1)                                                                           
  Adjust…                                                                       
  Earnin…                                                                       
  before     $     127,808    $     135,863    $      347,400    $     394,788  
  Income                                                                        
  Taxes                                                                         
  Provis…                                                                       
  for        $      27,511    $      26,295    $       75,552    $      81,629  
  Income                                                                        
  Taxes                                                                         
  Adjust…                                                                       
  Restru…              557              561             1,240            1,488  
  initia…                                                                       
  Net                                                                           
  invest…              247               39               284             -207  
  loss                                                                          
  (gain)                                                                        
  Realiz…                                                                       
  gain on                                                                       
  invest…                                                                       
  includ…                                                                       
  in                     —                —                22                —  
  net                                                                           
  invest…                                                                       
  loss                                                                          
  (gain)                                                                        
  above                                                                         
  Russia                                                                        
  decons…              785                —               785                —  
  impact                                                                        
  Gain                                                                          
  from                                                                          
  remeas…                                                                       
  of                     —                —                 —                —  
  equity                                                                        
  method                                                                        
  invest…                                                                       
  Transa…                                                                       
  costs                                                                         
  related                —              182                20              268  
  to                                                                            
  acquis…                                                                       
  Purcha…                                                                       
  accoun…                                                                       
  adjust…                                                                       
  related                —              172                49              172  
  to                                                                            
  acquis…                                                                       
  and                                                                           
  invest…                                                                       
  Other                                                                         
  special              788            1,078             2,815            1,078  
  items                                                                         
  Foreign                                                                       
  curren…                               -63                              2,014  
  effects                                                                       
  (1)                                                                           
  Adjust…                                                                       
  Provis…                                                                       
  for        $      29,888    $      28,264    $       80,767    $      86,442  
  Income                                                                        
  Taxes                                                                         
  Net                                                                           
  (Incom…                                                                       
  Loss                                                                          
  Attrib…    $        -226    $         -47    $         -382    $          76  
  to                                                                            
  Noncon…                                                                       
  Intere…                                                                       
  Net                                                                           
  (Incom…                                                                       
  Loss                                                                          
  Attrib…    $           6    $         142    $         -368    $         142  
  to                                                                            
  Redeem…                                                                       
  Noncon…                                                                       
  Intere…                                                                       
  Net                                                                           
  Income                                                                        
  Attrib…    $      32,602    $     127,927    $      192,849    $     318,445  
  to                                                                            
  AptarG…                                                                       
  Inc.                                                                          
  Adjust…                                                                       
  Restru…            1,651            1,607             3,473            4,301  
  initia…                                                                       
  Net                                                                           
  invest…              764              122               876             -638  
  loss                                                                          
  (gain)                                                                        
  Realiz…                                                                       
  gain on                                                                       
  invest…                                                                       
  includ…                                                                       
  in                     —                —                66                —  
  net                                                                           
  invest…                                                                       
  loss                                                                          
  (gain)                                                                        
  above                                                                         
  Russia            60,376                —            60,376                —  
  decons…                                                                       
  Gain                                                                          
  from                                                                          
  remeas…                                                                       
  of                     —          -26,518                 —          -26,518  
  equity                                                                        
  method                                                                        
  invest…                                                                       
  Transa…                                                                       
  costs                                                                         
  related                —              566                63              824  
  to                                                                            
  acquis…                                                                       
  Purcha…                                                                       
  accoun…                                                                       
  adjust…                                                                       
  related                —              976                96              976  
  to                                                                            
  acquis…                                                                       
  and                                                                           
  invest…                                                                       
  Other                                                                         
  special            2,307            3,322             8,084            3,322  
  items                                                                         
  Foreign                                                                       
  curren…                              -308                              7,852  
  effects                                                                       
  (1)                                                                           
  Adjust…                                                                       
  Net                                                                           
  Income                                                                        
  Attrib…    $      97,700    $     107,694    $      265,883    $     308,564  
  to                                                                            
  AptarG…                                                                       
  Inc.                                                                          
  Average                                                                       
  Number                                                                        
  of                64,147           66,630            64,373           67,043  
  Diluted                                                                       
  Shares                                                                        
  Outsta…                                                                       
                                                                                
                                       12                                       
                                                                                
                        Three                              Nine                 
                       Months                            Months                 
                        Ended                             Ended                 
                    September                         September                 
              2026        30,    2025           2026        30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  Income                                                                        
  Attribu…                                                                      
  to          $          0.51    $      1.92    $          3.00    $      4.75  
  AptarGr…                                                                      
  Inc. Per                                                                      
  Diluted                                                                       
  Share                                                                         
  Adjustm…                                                                      
  Restruc…               0.02           0.02               0.05           0.06  
  initiat…                                                                      
  Net                                                                           
  investm…               0.01              —               0.01          -0.01  
  loss                                                                          
  (gain)                                                                        
  Realized                                                                      
  gain on                                                                       
  investm…                                                                      
  included                                                                      
  in                        —              —                  —              —  
  net                                                                           
  investm…                                                                      
  loss                                                                          
  (gain)                                                                        
  above                                                                         
  Russia                 0.94              —               0.94              —  
  deconso…                                                                      
  Gain                                                                          
  from                                                                          
  remeasu…                                                                      
  of                        —          -0.40                  —          -0.40  
  equity                                                                        
  method                                                                        
  investm…                                                                      
  Transac…                                                                      
  costs                                                                         
  related                   —           0.01                  —           0.01  
  to                                                                            
  acquisi…                                                                      
  Purchase                                                                      
  account…                                                                      
  adjustm…                                                                      
  related                   —           0.02                  —           0.02  
  to                                                                            
  acquisi…                                                                      
  and                                                                           
  investm…                                                                      
  Other                                                                         
  special                0.04           0.05               0.13           0.05  
  items                                                                         
  Foreign                                                                       
  currency                                 —                              0.12  
  effects                                                                       
  (1)                                                                           
  Adjusted                                                                      
  Net                                                                           
  Income                                                                        
  Attribu…                                                                      
  to          $          1.52    $      1.62    $          4.13    $      4.60  
  AptarGr…                                                                      
  Inc. Per                                                                      
  Diluted                                                                       
  Share                                                                         
                                                                                
(1) Foreign currency effects are approximations of the adjustment necessary to
state the prior year earnings and earnings per share using current period
foreign currency exchange rates.
                                       13                                       
                                                                                
                                AptarGroup, Inc.                                
                                                                                
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) 
                                                                                
                                 (In Thousands)                                 
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  Cash                                                                          
  Provid…    $     167,598    $     177,606    $      389,778    $     386,306  
  by                                                                            
  Operat…                                                                       
  Capital          -69,006          -63,313          -191,965          -183,6…  
  Expend…                                                                       
  Procee…                                                                       
  from                   —                —                 —            3,308  
  Govern…                                                                       
  Grants                                                                        
  Free                                                                          
  Cash       $      98,592    $     114,293    $      197,813    $     206,014  
  Flow                                                                          
                                                                                
                                       14                                       
                                                                                
                                AptarGroup, Inc.                                
                                                                                
       Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)        
                                                                                
                     (In Thousands, Except Per Share Data)                      
                                                                                
                                           Three Months Ending                  
                                           December 31,                         
                                           Expected 2026          2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Income before Income Taxes                                      $     91,522  
  Adjustments:                                                                  
  Restructuring initiatives                                              4,048  
  Curtailment gain related to                                             -115  
  restructuring initiatives                                                     
  Net investment loss                                                    1,328  
  Transaction costs related to                                             368  
  acquisitions                                                                  
  Purchase accounting adjustments                                               
  related                                                                  645  
  to acquisitions and investments                                               
  Other special items                                                    3,960  
  Foreign currency effects (1)                                          -2,485  
  Adjusted Earnings before Income Taxes                           $     99,271  
  Provision for Income Taxes                                      $     17,252  
  Adjustments:                                                                  
  Restructuring initiatives                                              1,015  
  Curtailment gain related to                                              -30  
  restructuring initiatives                                                     
  Net investment loss                                                      325  
  Transaction costs related to                                             125  
  acquisitions                                                                  
  Purchase accounting adjustments                                               
  related                                                                  110  
  to acquisitions and investments                                               
  Other special items                                                      970  
  Foreign currency effects (1)                                            -468  
  Adjusted Provision for Income Taxes                             $     19,299  
  Net Loss Attributable to                                                      
  Noncontrolling                                                  $        130  
  Interests                                                                     
  Net Income Attributable to Redeemable                           $        -56  
  Noncontrolling Interests                                                      
  Net Income Attributable to                                                    
  AptarGroup,                                                     $     74,344  
  Inc.                                                                          
  Adjustments:                                                                  
  Restructuring initiatives                                              3,033  
  Curtailment gain related to                                              -85  
  restructuring initiatives                                                     
  Net investment loss                                                    1,003  
  Transaction costs related to                                             243  
  acquisitions                                                                  
  Purchase accounting adjustments                                               
  related                                                                  535  
  to acquisitions and investments                                               
  Other special items                                                    2,990  
  Foreign currency effects (1)                                          -2,017  
  Adjusted Net Income Attributable to                             $     80,046  
  AptarGroup, Inc.                                                              
  Average Number of Diluted Shares                                      65,796  
  Outstanding                                                                   
                                                                                
                                       15                                       
                                                                                
                                            Three Months Ending                 
                                            December 31,                        
                                            Expected 2026          2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Net Income Attributable to AptarGroup,                           $      1.13  
  Inc. Per Diluted Share                                                        
  Adjustments:                                                                  
  Restructuring initiatives                                               0.05  
  Curtailment gain related to                                                —  
  restructuring initiatives                                                     
  Net investment loss                                                     0.01  
  Transaction costs related to                                               —  
  acquisitions                                                                  
  Purchase accounting adjustments                                               
  related                                                                 0.01  
  to acquisitions and investments                                               
  Other special items                                                     0.05  
  Foreign currency effects (1)                                           -0.03  
  Adjusted Net Income Attributable to       $1.39 - $1.47          $      1.22  
  AptarGroup, Inc. Per Diluted Share (2)                                        
                                                                                
(1) Foreign currency effects are approximations of the adjustment necessary to
state the prior year earnings and earnings per share using current spot rates
for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the fourth
quarter of 2026, see non-GAAP section for full definition, is based on an
effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our
fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per
share and 19.4% on adjusted earnings per share.
                                       16                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ATR/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.